Skip to main content
Download PDF
  • Androgénes en 2001
  • Published:

Résumés des présentations du Symposium de Montpellier

Andrologie volume 12, pages 207–219 (2002)Cite this article

Références

  • Bennett, C.L., Tosteson, T.D., Schmitt, B., Weinberg, P.D., Ernstoff, M.S., Ross, S.D.: Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4129 patients using Flutamide. Prostate Cancer and Prostatic Disease, 2: 4–8, 1999.

    Article  Google Scholar 

  • Bolla, M., Gonzalez, D., Warde, P., et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N. Engl. J. Med., 1997, 337: 295–300.

    Article  PubMed  CAS  Google Scholar 

  • Brawer, M.K., Stamey, T.A., Fowler, J., Droller, M., Messing, E., Fair, W.R.: Perspectives on prostate cancer diagnosis and treatment: a roundtable. Urol., 2001, 58: 135–140.

    Article  PubMed  CAS  Google Scholar 

  • Candas, B., Cusan, L., Gomez, et al.: Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 2000, 45: 19–35.

    Article  PubMed  CAS  Google Scholar 

  • Candas, B., Labrie, F.: Unequal decrease of prostate cancer specific death rates through the Province of Quebec between 1991 and 1999. 14th Int. Symposium J. Steroid Biochem. Mol. Biol., Québec, Canada, 2000, P. 133, Abst. 86-P.

  • Caubet, J.F., Tosteson, T.D., Dong, E.W., Naylon, E.M., Whiting, G.W., Ernstoff, M.S., Ross, S.D.: Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urol., 1997, 49: 71–78.

    Article  PubMed  CAS  Google Scholar 

  • Crawford, E.D., Eisenberger, M.A., McLeod, D.G., et al.: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 1989, 321: 419–424.

    PubMed  CAS  Google Scholar 

  • Denis, L.J., Keuppens, F., Smith, et al.: Maximal androgen blockade: final analysis of EORTC Phase III trial 30853. Eur. Urol., 1998, 33: 144–151.

    Article  PubMed  CAS  Google Scholar 

  • Dijkman, G.A., Janknegt, R.A., Dereijke, T.M., Debruyne, F.M.J.: Long-term efficacy and safety of nilutamide plus castration in advanced prostate-cancer, and the significance of early prostate specific antigen normalization. J. Urol., 1997, 158: 160–163.

    Article  PubMed  CAS  Google Scholar 

  • Granfors, T., Modig, H., Damber, J.E., Tomic, R.: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J. Urol., 1998, 159: 2030–2034.

    Article  PubMed  CAS  Google Scholar 

  • Hanks, G.E., Lu, J., Machtay, et al.: RTOG Protocol 92-02: A Phase III Trial of the Use of Long Term Androgen Suppression Following Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, USA, 2000, 1284.

  • Janknegt, R.A., Abbou, C.C., Bartoletti, R., et al.: Orchiectomy and Nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J. Urol., 1993, 149: 77–83.

    PubMed  CAS  Google Scholar 

  • Labrie, F.: Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer. J. Sci. Am., 2000, 6: S182-S187.

    Google Scholar 

  • Labrie, F., Bélanger, A., Cusan, L., et al.: Antifertility effects of LHRH agonists in the male. J. Androl., 1980, 1: 209–228.

    CAS  Google Scholar 

  • Labrie, F., Bélanger, A., Cusan, L., et al.: History of LHRH agonists and combination therapy in prostate cancer. Endocrine-Related Cancer, 1996a, 3: 243–278.

    Article  CAS  Google Scholar 

  • Labrie, F., Candas, B., Cusan, L., et al.: Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostatespecific antigen. Urol., 1996b, 47: 212–217.

    Article  PubMed  CAS  Google Scholar 

  • Labrie, F., Candas, B., Dupont, A., et al.: Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 1999a, 38: 83–91.

    Article  PubMed  CAS  Google Scholar 

  • Labrie, F., Cusan, J., Gomez, J., Levesque, Candas, B.: Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Aging Male, 1999b, 2: 33–43.

    Article  Google Scholar 

  • Labrie, F., Dupont, A., Bélanger, A: Complete androgen blockade for the treatment of prostate cancer. In de Vita, V.T., Hellman, S. and Rosenberg, S.A., eds. Important Advances in Oncology. Philadelphia, J.B. Lippincott, 1985: 193–217.

    Google Scholar 

  • Labrie, F., Dupont, A., Suburu, R., et al.: Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 1992, 147: 846–852.

    PubMed  CAS  Google Scholar 

  • Makinen, T., Tammela, T.L., Hakama, M., et al.: Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests. J Urol, 2001, 166: 1339–1342

    Article  PubMed  CAS  Google Scholar 

  • Messing, E.M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E.D., Trump, D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N. Engl. J. Med., 1999, 341: 1781–1788.

    Article  PubMed  CAS  Google Scholar 

  • Pilepich, M.V., Caplan, R., Byhardt, et al.: Phase III trial of androgen suppression using Goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J. Clin. Oncol., 1997, 15: 1013–1021.

    PubMed  CAS  Google Scholar 

  • Prostate Cancer Triallists’ Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet, 2000, 355: 1491–1498.

    Article  Google Scholar 

  • Shröder, F.H., Maas, P.V.D., Beemsterboer, P., Kruger, A.B., Hoedemaeker, R., Rietbergen, J.: Evaluation of the digital rectal examination as a screening test for prostate cancer. J. Natl. Cancer Inst., 1998, 1817–1823.

  • Shröder, F.H., Roobol-Bouts, M., Vis, A.N., Kwast, T.V.D., Kranse, R.: Prostate-specific antigen-based early detection of prostate cancervalidation of screening without rectal examination. Urol., 2001, 57: 83–90.

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Résumés des présentations du Symposium de Montpellier. Androl. 12, 207–219 (2002). https://doi.org/10.1007/BF03034967

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03034967

Basic and Clinical Andrology

ISSN: 2051-4190